Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02797470 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
A Phase 1 study of HIV Infection and Recurrent Follicular Lymphoma, sponsored by AIDS Malignancy Consortium.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 4
- Study locations
NCT02797470 is a Phase 1 study of HIV Infection and Recurrent Follicular Lymphoma that is active but no longer recruiting, run by AIDS Malignancy Consortium. The registered enrollment target is 11 participants, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT02797470, a Phase 1 study of HIV Infection and Recurrent Follicular Lymphoma, is active but no longer recruiting, sponsored by AIDS Malignancy Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
Study Locations (4)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Medical Center-Parnassus - San Francisco
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-06-23 |
| Est. Completion | 2036-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02797470
The ClinicalTrials.gov registry entry for NCT02797470 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (95% lower). The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with HIV Infection appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02797470 reports 4 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT02797470 about?
NCT02797470 is a clinical study titled "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant". This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response receiving stem cell transplant. In gene therapy, small stretches of deoxy...
What is the current status of trial NCT02797470?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-06-23. Estimated completion is 2036-03.
What conditions does trial NCT02797470 study?
This clinical trial studies the following conditions: HIV Infection, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma.
What interventions are being tested in trial NCT02797470?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT02797470?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02797470 being conducted?
This trial has 4 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Twins Study of Gene Therapy for HIV Infection
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.